; The goal of Project 3 is to provide high-resolution structural information that will: (1) further our understanding ofthe mechanism by which allosteric modulators regulate GPCR function, (2) form the basis for docking experiments to identify new subtype selective allosteric modulators, and (3) provide structural information for optimizing docking hits. The X-ray structures of GPCRs such as the P2AR (in both inactive and active states), the muscarinic M2, and M3, and the p- and 5-opioid receptors have enabled this project. These targets were initially selected for structural studies in the Kobilka lab based on their interesting pharmacological properties: the P2AR, an established model system for GPCR signaling;the muscarinic receptors, model systems for allosteric regulation;and the opioid receptors, which have been shown to function as homo- and hetero-oligomers, and for which there is a wealth of both peptide and small molecule ligands. The existing structures will form the basis for initial docking studies proposed in Project 1. We will work with Project 1, Project 2, and the Medicinal Chemistry core to identify and optimize novel ligands through iterative rounds of crystallography and chemical optimization. Finally, the Kobilka lab will work with the Sunahara (Project 2) and Shoichet (Project 1) labs to correlate chemical structure and functional properties with structural changes and protein dynamics determined by biochemical and biophysical approaches.
Specific Aims :
Aim 1. Determine active-state structures ofthe M2 and M3 muscarinic receptors.
Aim 2. Obtain structures of receptors bound to positive and negative allosteric modulators.
Aim 3. Determine structures of intermediate conformational states ofthe B2AR.
Aim 4. Determine the structure of ligands bound to the B-opioid receptor oligomerization interface.
Aim 5. Characterize the effect of allosteric modulators on receptor structure and dynamics.
This Project will obtain high resolution structural information that will enable the development of more selective and effective drugs for GPCRs, which are the largest family of membrane proteins in the human genome. Drugs acting on GPCRs can have an impact on a broad spectrum of diseases including: cardiovascular disease, pulmonary disease, inflammation, diabetes and obesity, behavioral disorders and Alzheimer's disease.
|Korczynska, Magdalena; Clark, Mary J; Valant, Celine et al. (2018) Structure-based discovery of selective positive allosteric modulators of antagonists for the M2 muscarinic acetylcholine receptor. Proc Natl Acad Sci U S A 115:E2419-E2428|
|Liu, Xiangyu; Ahn, Seungkirl; Kahsai, Alem W et al. (2017) Mechanism of intracellular allosteric ?2AR antagonist revealed by X-ray crystal structure. Nature 548:480-484|
|Fish, Inbar; Stößel, Anne; Eitel, Katrin et al. (2017) Structure-Based Design and Discovery of New M2 Receptor Agonists. J Med Chem 60:9239-9250|
|Stößel, Anne; Brox, Regine; Purkayastha, Nirupam et al. (2017) Development of molecular tools based on the dopamine D3 receptor ligand FAUC 329 showing inhibiting effects on drug and food maintained behavior. Bioorg Med Chem 25:3491-3499|
|Brea, Roberto J; Cole, Christian M; Lyda, Brent R et al. (2017) In Situ Reconstitution of the Adenosine A2A Receptor in Spontaneously Formed Synthetic Liposomes. J Am Chem Soc 139:3607-3610|
|Manglik, Aashish; Lin, Henry; Aryal, Dipendra K et al. (2016) Structure-based discovery of opioid analgesics with reduced side effects. Nature 537:185-190|
|DeVree, Brian T; Mahoney, Jacob P; Vélez-Ruiz, Gisselle A et al. (2016) Allosteric coupling from G protein to the agonist-binding pocket in GPCRs. Nature 535:182-6|
|Thal, David M; Sun, Bingfa; Feng, Dan et al. (2016) Crystal structures of the M1 and M4 muscarinic acetylcholine receptors. Nature 531:335-40|
|Mahoney, Jacob P; Sunahara, Roger K (2016) Mechanistic insights into GPCR-G protein interactions. Curr Opin Struct Biol 41:247-254|
|Kruse, Andrew C; Hu, Jianxin; Kobilka, Brian K et al. (2014) Muscarinic acetylcholine receptor X-ray structures: potential implications for drug development. Curr Opin Pharmacol 16:24-30|
Showing the most recent 10 out of 15 publications